LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) will host a teleconference call today at 2:30 p.m. EST to review its drug development programs and financial results for the third quarter of 2008. Duska's chief executive officer, James S. Kuo, MD, MBA, will host the call and there will be a question-and-answer session immediately afterward.
To participate in the teleconference, please call toll-free 800.895.0198 (direct dial 785.424.1053) five minutes prior to the scheduled starting time in order to register for the call. A replay of the call will be available after its completion for ten days at 800.283.8217 (direct dial 402.220.0868).
"We have made remarkable progress in our two lead drug development programs this past quarter as we prepare for a Phase 2 trial for one compound and a Phase 3 trial for the other early next year," said Dr. Kuo. "In addition, we strengthened the intellectual property position around our ATPotent program through licenses with several inventors."
Highlights of accomplishments included: -- Submission of a pivotal Phase 3 ATPace clinical trial protocol for review under a Special Protocol Assessment (SPA) procedure with the U.S. Food and Drug Administration (FDA). Subject to securing an agreement with the FDA, Duska intends to initiate a single, prospective, double-blind, placebo-controlled and randomized Phase 3 clinical trial with ATPace, its lead product. The trial will be aimed at demonstrating clinical safety and efficacy of ATPace in treating emergency room patients presenting with paroxysmal supraventricular tachycardia (PSVT). PSVT is a condition characterized by a rapid, regular heart rate originating in the atria, which affects approximately 570,000 patients in the United States alone; in addition, 89,000 new cases per
|SOURCE Duska Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved